HDAC INHIBITORS MARKET ANALYSIS

Hdac Inhibitors MarketSize and Trends

Increasing R&D activities for cancer is expected to boost HDAC inhibitors market during the forecast period

In February 2015, Novartis received the U.S. FDA approval for Farydak capsules along with dexamethasone and bortezomib*, for patients suffering from multiple myeloma, who previously received minimum two regimens. FDA approval of few HDAC inhibitors for cancer treatment has created interest in finding new products as potential anti-cancer drugs. Moreover, increasing R&D activities for the treatment of cancer and other neurological disorders is one of the prime factors responsible for growth of the HDAC inhibitors market. Around 350 clinical trials were carried out or under process using HDACi as single therapeutic or along with other targeted agents against different human diseases. However, uncertainty issues about the therapeutic potential of HDAC inhibitors and stringent reimbursement policies is expected to impede growth of the market in near future. For instance, there can be significant delays in gaining reimbursement and coverage for newly approved drugs by FDA or other foreign regulatory authorities.

Market Taxonomy

On the basis of application, the HDAC inhibitors market is segmented into:

• Oncology
• Neurology
• Other

On the basis of end user, the HDAC inhibitors market is segmented into:

• Hospitals
• Oncology Clinics
• Other

Market Trends